Open AccessPeripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors
Author(s) -
Wenhui Liu,
Yiping Liu,
Fengwang Ma,
Bao Sun,
Ying Wang,
Jun Luo,
Mouze Liu,
Zhicheng Luo
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s293200
Subject(s) - medicine , neutrophil to lymphocyte ratio , adverse effect , lung cancer , rash , lymphocyte , gastroenterology , platelet , nivolumab , cancer , oncology , immunotherapy
Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with advanced non-small-cell lung cancer (aNSCLC), but immune-related adverse events (irAEs) have been evidenced curtailed the clinical use of them.